Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$18.46 USD

18.46
485,115

+0.80 (4.53%)

Updated Nov 11, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus

by Zacks Equity Research

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.

Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues

by Zacks Equity Research

Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.

Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Acadia (ACAD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

by Zacks Equity Research

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

by Zacks Equity Research

Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

by Zacks Equity Research

Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 108.33% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.

ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.

Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results

by Zacks Equity Research

Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.

Kodiak (KOD) Down as Late-Stage DME Studies Fail

by Zacks Equity Research

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.

Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche

by Zacks Equity Research

Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.